The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of sunvozertinib in treatment naïve NSCLC patients with EGFR exon20 insertion mutations.
 
Yan Xu
No Relationships to Disclose
 
James Chih-Hsin Yang
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Amgen (Inst); AstraZeneca; AstraZeneca (Inst); Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; Daiichi Sankyo (Inst); G1 Therapeutics; GlaxoSmithKline (Inst); Hansoh; Incyte; Janssen (Inst); Lilly; Merck Serono; Merck Serono (Inst); MSD Oncology; MSD Oncology (Inst); Novartis; Novartis (Inst); Ono Pharmaceutical; Pfizer; Takeda; Takeda (Inst); Yuhan
Travel, Accommodations, Expenses - Pfizer
 
Chao-Hua Chiu
No Relationships to Disclose
 
Ping-Chih Hsu
No Relationships to Disclose
 
Paul Mitchell
No Relationships to Disclose
 
Chia lun Chang
No Relationships to Disclose
 
Tom John
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; MSD Oncology; Roche/Genentech
Consulting or Advisory Role - Amgen (Inst); AstraZeneca; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Gilead Sciences; Ignyta; Merck KGaA; MSD Oncology; Novartis; Pfizer; PharmaMar (Inst); Roche/Genentech; Specialised Therapeutics
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche; Roche
 
Lyudmila Bazhenova
Stock and Other Ownership Interests - Epic Sciences
Consulting or Advisory Role - Abbvie; Bayer; Daichi; Elevation Oncology; Genentech/Roche; InterVenn Biosciences; Johnson and Johnson; Merck; Mirati Therapeutics; neuvogen; Novocure; ORCIC; Regeneron; Sanofi; Turning Point Therapeutics
 
Tae Min Kim
Consulting or Advisory Role - AstraZeneca/MedImmune; Janssen Oncology; Novartis; Regeneron; Samsung Bioepis; Takeda; Yuhan
Speakers' Bureau - IMBdx; Janssen Research & Development; Takeda
Research Funding - AstraZeneca
(OPTIONAL) Uncompensated Relationships - AstraZeneca/MedImmune; Boryung; Novartis; Roche/Genentech
 
Ching Wan Yip
No Relationships to Disclose
 
Mengzhao Wang
No Relationships to Disclose
 
Pasi A. Janne
Stock and Other Ownership Interests - Gatekeeper Pharmaceuticals; Loxo
Consulting or Advisory Role - Abbvie; Accutar Biotech; Allorion Therapeutics; Araxes Pharma; AstraZeneca; Bayer; Biocartis; Biocartis; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Duality Biologics; Eisai; Frontier Medicines; Hongyun Biotech; Ignyta; Lilly; LOXO; Merrimack; Merus; Mirati Therapeutics; Monte Rosa Therapeutics; Novartis; Nuvalent, Inc.; Pfizer; Roche/Genentech; Sanofi; Scorpion Therapeutics; SFJ Pharmaceuticals Group; Silicon Therapeutics; Syndax; Takeda; Transcenta; Voronoi Health Analytics
Research Funding - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Lilly; Puma Biotechnology; Revolution Medicines; Takeda
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp. I receive post-marketing royalties from this invention
 
Caicun Zhou
No Relationships to Disclose